WO1999045112A3 - Gene chd1 de susceptibilite aux maladies coronariennes lie au chromosome 11 - Google Patents

Gene chd1 de susceptibilite aux maladies coronariennes lie au chromosome 11 Download PDF

Info

Publication number
WO1999045112A3
WO1999045112A3 PCT/US1999/004682 US9904682W WO9945112A3 WO 1999045112 A3 WO1999045112 A3 WO 1999045112A3 US 9904682 W US9904682 W US 9904682W WO 9945112 A3 WO9945112 A3 WO 9945112A3
Authority
WO
WIPO (PCT)
Prior art keywords
chd1
heart disease
coronary heart
gene
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/004682
Other languages
English (en)
Other versions
WO1999045112A2 (fr
Inventor
Dennis G Ballinger
Wei Ding
Susanne Wagner
Mark A Hess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myriad Genetics Inc
Original Assignee
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Genetics Inc filed Critical Myriad Genetics Inc
Priority to AU30680/99A priority Critical patent/AU3068099A/en
Publication of WO1999045112A2 publication Critical patent/WO1999045112A2/fr
Publication of WO1999045112A3 publication Critical patent/WO1999045112A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur le gène (CHD1) humain de susceptibilité aux maladies coronariennes dont certains allèles sont en relation avec ladite susceptibilité, sur des mutations des lignées germinales du gène CHD1 et leur utilisation dans le diagnostic de la prédisposition aux maladies coronariennes et des troubles du métabolisme, dont l'hypoalphalipoprotéinémie, l'hyperlipidémie familiale combinée, le syndrome X de résistance à l'insuline, ou les troubles multiples du métabolisme, l'obésité, le diabète et l'hypertension dyslipidémique, sur la thérapie présymptomatique d'individus porteurs d'allèles délétères (dont la thérapie génique, la thérapie par remplacement de protéines ou l'administration de protéines mimétiques et d'inhibiteurs), et sur le criblage de médicaments de thérapie des dyslipidémies.
PCT/US1999/004682 1998-03-04 1999-03-04 Gene chd1 de susceptibilite aux maladies coronariennes lie au chromosome 11 Ceased WO1999045112A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU30680/99A AU3068099A (en) 1998-03-04 1999-03-04 Chromosome 11-linked coronary heart disease susceptibility gene chd1

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3494198A 1998-03-04 1998-03-04
US09/034,941 1998-03-04
US8093498P 1998-04-06 1998-04-06
US60/080,934 1998-04-06

Publications (2)

Publication Number Publication Date
WO1999045112A2 WO1999045112A2 (fr) 1999-09-10
WO1999045112A3 true WO1999045112A3 (fr) 1999-11-04

Family

ID=26711582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/004682 Ceased WO1999045112A2 (fr) 1998-03-04 1999-03-04 Gene chd1 de susceptibilite aux maladies coronariennes lie au chromosome 11

Country Status (2)

Country Link
AU (1) AU3068099A (fr)
WO (1) WO1999045112A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104050344A (zh) * 2013-09-30 2014-09-17 西安时代基因健康科技有限公司 冠心病的表征参数的获取方法
CN116144753A (zh) * 2022-12-27 2023-05-23 湖南家辉生物技术有限公司 一种致病基因chd1突变位点的应用及检测试剂

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
HILLIER ET AL.: "The WashU-Merck EST Project", EMBL SEQUENCE DATABASE, 7 June 1996 (1996-06-07), HEIDELBERG DE, XP002114882 *
HILLIER ET AL.: "WashU-merck EST Project 1997", EMBL SEQUENCE DATABASE, 25 April 1997 (1997-04-25), HEIDELBERG DE, XP002114883 *
LEE ET AL., GENOMICS, vol. 43, 1997, pages 191 - 201 *
LEE ET AL.: "Zinc finger protein", EMBL SEQUENCE DATABASE, 1 November 1996 (1996-11-01), HEIDELBERG DE, XP002114884 *
MONACO ET AL., GENOMICS, vol. 52, 1998, pages 358 - 362, XP002114888 *
MONACO ET AL.: "Homo sapiens ZNF202 beta (ZNF202) mRNA, complete cds", EMBL SEQUENCE DATABASE, 16 November 1998 (1998-11-16), HEIDELBERG DE, XP002114887 *
STOKES ET AL.: "DNA.binding and chromatin localization properties of CHD1", MOLECULAR AND CELLULAR BIOLOGY, vol. 15, no. 5, May 1995 (1995-05-01), pages 2745 - 2753, XP002114885 *
WOODAGE ET AL.: "Characterization of the CHD family of proteins", PROC NATL ACAD SCI USA, vol. 94, October 1997 (1997-10-01), pages 11472 - 11477, XP002114886 *

Also Published As

Publication number Publication date
WO1999045112A2 (fr) 1999-09-10
AU3068099A (en) 1999-09-20

Similar Documents

Publication Publication Date Title
Ellingrod et al. Weight gain associated with the− 759C/T polymorphism of the 5HT2C receptor and olanzapine
Lidar et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization
WO2002054187A3 (fr) Recueillir et gerer des informations cliniques
Wu et al. Association of XPD polymorphisms with severe toxicity in non–small cell lung cancer patients in a Chinese population
Okamoto et al. Hydrocephalus and Hirschsprung's disease in a patient with a mutation of L1CAM.
Gutmann Eliminating barriers to personalized medicine: learning from neurofibromatosis type 1
Galluzzo et al. Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature
Wanner et al. Therapeutic goals in Fabry disease: Recommendations of a European expert panel, based on current clinical evidence with enzyme replacement therapy
McDermott Genetic clues to understanding periodic fevers, and possible therapies
Shen et al. Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study
Kawamata et al. Mutations in LGI1 gene in Japanese families with autosomal dominant lateral temporal lobe epilepsy: the first report from Asian families
Fingerhutová et al. Muckle-Wells syndrome across four generations in one Czech family: natural course of the disease
WO1999045112A3 (fr) Gene chd1 de susceptibilite aux maladies coronariennes lie au chromosome 11
Abrahams-October et al. Genetic association of solute carrier transporter gene variants with metformin response
Molnar et al. Medical-psychiatric unit patients compared with patients in two other services
Garfunkel et al. Pharmacogenetics of metformin for medication-induced weight gain in autism spectrum disorder
Jung et al. Phenotypic variability of episodic ataxia type 2 mutations: a family study
WO2003097683A3 (fr) Gene humain de predisposition a l'obesite et utilisations dudit gene
Hershkovitz et al. Familial cutaneous collagenomas resulting from a novel mutation in LEMD3
Porterfield et al. A New Era in the Medical Management of Obesity
IL179744A0 (en) Human obesity susceptibility gene encoding a potassium voltage-gated channel and uses thereof
Assimon et al. MZ-301 is a small molecule inhibitor of APOL1 pore function that attenuates albuminuria in a mouse model of APOL1-Mediated kidney disease: FR-PO318
Matsubayashi et al. Cancer treatment and management for elderly patients 80 years of age or older with malignant solid tumors.
Rotty et al. Interleukin-2: a potential treatment option for postherpetic neuralgia?
Eadon et al. Design and rationale of GUARDD-US: a pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension: FR-PO320

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase